Market Overview

UPDATE: Jefferies Lowers PT on Amarin on Continued ANCHOR Partnership Discussion

Share:
Related AMRN
Benzinga's Top Initiations
Amarin Offers New Clinical, Pre-Clinical Data at ACC Meeting Related to Effect of EPA Therapy in Statin-Treated Patients

In a report published Friday, Jefferies analyst Thomas Wei reiterated a Buy rating on Amarin (NASDAQ: AMRN), but lowered the price target from $24.00 to $20.00.

In the report, Jefferies noted, “We remain focused on the FDA panel meeting in October for ANCHOR and the launch of ANCHOR in 1H14 as the key catalysts for AMRN shares. The company remains in negotiations for a pharma partnership for ANCHOR, but also discussed the merits of self-commercialization.”

Amarin closed on Thursday at $5.31.

Latest Ratings for AMRN

DateFirmActionFromTo
May 2016JefferiesInitiates Coverage onBuy
Mar 2015HC WainwrightUpgradesBuy
Feb 2015SunTrust Robinson HumphreyUpgradesNeutralBuy

View More Analyst Ratings for AMRN
View the Latest Analyst Ratings

Posted-In: Jefferies Thomas WeiAnalyst Color Price Target Analyst Ratings

 

Related Articles (AMRN)

View Comments and Join the Discussion!